Abstract
The natural history of infection with hepatitis C is incompletely understood, because the exact date of acquisition of infection is often unknown, many patients with hepatitis C escape detection, and current, widely used treatments may affect outcome. Seeff (1) proposed that the most accurate study to evaluate the natural history of hepatitis C should have five basic components. First, the date of onset of acute hepatitis C should be documented to properly determine duration of disease. Second, the study should include the full spectrum of acute disease, to avoid bias toward ascertainment of only the more severe forms of the disease. Third, the study should encompass the whole disease process, with complete follow-up to resolution of disease or clinical end points, regardless of the duration of disease must be examined. Fourth, the outcome of disease must be examined in the absence of treatment that could modify the course of the disease. Fifth, properly matched controls, followed with the same clinical intensity as patients with hepatitis C should be included. Another consideration is that studies of natural history should examine cohorts that are representative of the overall population with the infection. Unfortunately, no single study meets all of these criteria. Nonetheless, there are numerous studies of natural history and disease progression that shed light on the nature of this indolent, but highly significant chronic liver disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Seeff LB. Natural history of hepatitis C. Hepatology 1997; 26(Suppl 1): 21S–28S.
Alter MJ, Kruszon-Moran D, Nainan OV, et al. Prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556— 562.
Cohen J. Scientifiic challenge of hepatitis C. Science 1999; 285: 26–30.
Heintges T, Wands JR. Hepatitis C virus: epidemiology and transmission. Hepatology 1997; 26: 521–526.
Delage G, Infante-Rivard C, Chiavetta J, et al. Risk factors for acquisition of hepatitis C virus infection in blood donors: results of a case-control study. Gastroenterology 1999; 116: 893–899.
Serfaty L, Giral P, Elghouzzi MH, et al. Risk factors for hepatitis C virus infection in hepatitis C virus antibody ELISA-positive blood donors according to RIBA-2 status: a case-control survey. Hepatology 1993; 17: 183–187.
Williams I. Epidemiology of hepatitis C in the United States. Am J Med 1999; 107: 2S–9S.
Murphy EL, Bryzman SM, Glynn SA, et al., for the NHLBI Retrovirus Epidemiology Donor Study (REDS). Risk factors for hepatitis C virus infection in United States blood donors. Hepatology 2000; 31: 756–762.
Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C (HCV) infection and HCV-related chronic disease. MMWR 1998; 47: 1–38.
Conte D, Fraquelli M, Prati D, et al. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology 2000; 31: 751–755.
Frank C, Mohamed MK, Strickland GT, et al. Role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355: 887–891.
Abdel-Aziz F, Habib M, Mohamed MK, et al. Hepatitis C virus (HCV) infection in a community in the Nile delta: population description and HCV prevalence. Hepatology 2000; 32: 111–115.
Kiyosawa K, Tanaka E, Sodeyama T, et al., and the South Kiso Hepatitis Study Group. Transmission of hepatitis C in an isolated area in Japan: community-acquired infection. Gastroenterology 1994; 106: 1596–1602.
Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26: 62S–65S.
World Health Organization. Hepatitis C. Weekly Epidemiol Rec 1997; 10: 65–69.
Alter MJ, Mast EE. Epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994; 23: 427–435.
Thiele DL. Viral hepatitis and acute liverfailure. In: Acute Liver Failure (Lee WM, Williams R, eds.), Cambridge, UK: Cambridge University Press, 1997, pp. 10–18.
Schiodt FV, Atillasoy E, Shakil AO, et al. Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl Surg 1999; 5: 29–34.
Kenny-Walsh E for the Irish Hepatology Research Group. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999; 340: 1228–1233.
Wiese M, Berr F, LaFrenz M, et al., the East German Hepatitis C Study Group. Low frequency of cirrhosis in a hepatitis C (genotype 1B) single-source outbreak in Germany: a 20-year multicenter study. Hepatology 2000; 32: 91–96.
Yoshiba M, Dehara K, Inoue K, et al. Contribution of hepatitis C virus to non-A, non-B fulminant hepatitis in Japan. Hepatology 1994; 19: 829–835.
Chu CM, Sheen IS, Liaw YF. Role of hepatitis C virus in fulminant viral hepatitis in an area with endemic hepatitis A and B. Gastroenterology 1994; 107: 189–195.
Villamil FG, Hu KQ, Yu CH, et al. Detection of hepatitis C virus with RNA polymerase chain reaction in fulminant hepatic failure. Hepatology 1995; 22: 1379–1386.
Farci P, Alter HJ, Shimoda A, et al. Hepatitis C virus-associated fulminant hepatic failure. N Engl J Med 1996; 335: 631–634.
Hoofnagle JH. Hepatitis C: clinical spectrum of disease. Hepatology 1997; 26: 15S–20S.
Kiiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion non-A, non-B hepatitis and hepatocellular carcinoma. Analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671–675.
Tong MJ, El-Farra NS, Reikes AR, et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463–1466.
Di Bisceglie AM, Goodman ZD, Ishak KG, et al. Long-term clinical and histologi-cal follow-up of chronic posttransfusion hepatitis. Hepatology 1991; 14: 969–974.
Hopf U, Moller B, Kuther D, et al. Long-term follow-up of posttransfusion and sporadi chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). J Hepatol 1990; 10: 69–76.
Koretz RL, Abbey H, Coleman E, et al. Non-A, non-B post-transfusion hepatitis: looking back in the second decade. Ann Intern Med 1993; 119: 110–115.
Mattson L, Sonnerborg A, Weiland 0. Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. Liver 1993; 13: 274–278.
Tremolada F, Casarin C, Alberti A, et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992; 16: 273–281.
Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992; 327: 1906–1911.
Rodger AJ, Roberts S, Lanigan A, et al. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology 2000; 32: 582–587.
Seeff LB, Miller RN, Rabkin CS, et al. 45-Year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000; 132: 105–111.
Piton A, Poynard T, Imbert-Bismut F, et al. Factors associated with serum transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with hepatitis C. MULTIVIRC group. Hepatology 1998; 27: 1213–1219.
Puoti C, Magrini A, Stati T, et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 1997; 26: 1393–1398.
NIH Consensus Statement. Management of Hepatitis C. Hepatology 1997; 15:1–41.
Mathurin P, Moussalli J, Cadranel JF, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998; 27: 868–872.
DiBisceglie AM. Chronic hepatitis C viral infection in patients with normal serum alanine aminotransferases. Am J Med 1999; 107: 53S–55S.
Jamal MM, Soni A, Quinn PG, et al. Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the southwestern United States. Hepatology 2000; 30: 1307–1311.
Persico M, Persico E, Suozzo R, et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000; 118: 760–764.
Seeff LB. Natural history of hepatitis C. Am J Med 1999; 107: l0S–15S.
De Bac C, Stroffolini T, Gaeta GB, et al. Pathogenic factors in cirrhosis with and without hepatocellular carcinoma: a multicenter Italian study. Hepatology 1994; 20: 1225–1230.
Koff RS, Dienstag JL. Extrahepatic manifestations of hepatitis C and the associa-tion with alcoholic liver disease. Semin Liver Dis 1995; 15: 101–109.
Takahashi M, Yamada G, Miyamoto R, et al. Natural course of chronic hepatitis C. Am J Gastroenterol 1993; 88: 240–243.
Poynard T, Bedossa P, Opolon P. Natural history of liver fiibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825–832.
Yano M, Kumada H, Hage M, et al. Long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23: 1334–1340.
Vaquer P, Canet R, Llompart A, et al. Histological evolution of chronic hepatitis C. Factors related to progression. Liver 1994; 14: 265–269.
Noda K, Yoshihara H, Suzuki K, et al. Progression of type C chronic hepatitis to liver cirrhosis and hepatocellular carcinoma: its relationship to alcohol drinking and the age of transfusion. Alcohol Exp Res 1996; 20: 92–100A.
Merican I, Sherlock S, McIntyre N, Dusheiko GM. Clinical, biochemical and histological features in 102 patients with chronic hepatitis C virus infection. Q J Med 1993; 86: 119–125.
Perasso A, Testino G, Ansaldi F, et al. r-Interferon alfa-2b/ribavirin combined therapy followed by low-dose r-interferon alfa-2b in chronic hepitis C interferon nonresponders. Hepatology 1999; 29: 297–298.
Friedman SL. Evaluation of fibrosis and hepatitis C. Am J Med 1999; 107: 27S–30S.
Gerber MA. Histopathology of HCV infection. Clin Liver Dis 1997; 1: 530–602.
Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large prospective cohort study. Hepatology 1998; 28: 1687–1695.
Hagiwara H, Hayashi N, Mita E, et al. Quantitation of hepatitis C virus RNA in serum of asymptomatic blood donors and patients with type C chronic liver disease. Hepatology 1993; 17: 545–550.
Nousbaum JB, Pol S, Nalpas B, et al. Collaborative Study Group. Hepatitis C virus type lb (II) infection in France and Italy. Ann Intern Med 1995; 122: 161–168.
Gretch D, Corey I, Wilson J, et al. Assessment of hepatitis C virus RNA levels by quantitative competitive RNA polymerase chain reaction: high-titer viremia correlates with advanced stage of disease. J Infect Dis 1994; 169: 1219–1225.
Kato N, Yokosuka O, Hosoda K, et al. Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction: increase of the virus in advanced liver disease. Hepatology 1993; 18: 16–20.
Silini E, Bono F, Cividini A, et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology 1995; 21: 285–290.
Honda M, Kaneko S, Sakai A, et al. Degree of diversity of hepatitis C quasispecies and progression of liver disease. Hepatology 1994; 20: 1144–1151.
Dienstag JL. The natural history of chronic hepatitis C and what we should do about it. Gastroenterology 1997; 112: 651–655.
Jove J, Sanchez-Taplas M, Bruguera M, et al. Posttransfusional versus sporadic non-A, non-B chronic hepatitis: a clinicopathological and evolutive study. Liver 1988; 8: 42–47.
Gordon SC, Elloway RS, Long JC, Dmuchowski CF. Pathology of hepatitis C as a function of mode of transmission: blood transfusion vs intravenous drug use. Hepatology 1993; 18: 1338–1343.
Alter MJ, Margolis HS, Krawczynski K, et al. Natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992; 327: 1899–1905.
Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D, and the Study Group for the Prevalence and Epidemiology of Hepatitis C Virus. Hepatology 1997; 26: 485–490.
Gordon SC, Bayati N, Silverman AL. Clinical outcome of hepatitis C as a function of mode of transmission. Hepatology 1998; 28: 562–567.
Badizadegan K, Jonas MM, Ott MJ, et al. Histopathology of the liver in children with chronic hepatitis C viral infection. Hepatology 1998; 28: 1416–1423.
Guido M, Rugge M, Jara P. Chronic hepatitis C in children: the pathological and clinical spectrum. Gastroenterology 1998; 115: 1525–1529.
Vogt M, Lang T, Frosner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999; 341: 866–870.
Jonas MM. Hepatitis C infection in children. N Engl J Med 1999; 341: 912–913.
Chang KM. Mechanisms of chronicity in hepatitis C virus infection. Gastroenterology 1998; 115: 1015–1018.
Tsai SL, Chen YM, Chen MH, et al. Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity. Gastroenterology 1998; 115: 954–966.
Cerny A, Chisari FV. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology 1999; 30: 595–601.
Gretch D, Corey I, Wilson J, et al. Assessment of hepatitis C virus RNA levels by quantitative competitative RNA polymerase chain reaction: high-titer viremia correlates with advanced stage of disease. J Infect Dis 1994; 196: 1219–1225.
Kato N, Yokosuka O, Hosoda K, et al. Quantification of hepatitis C virus by competitive reverse transcription polymerase chain reaction: increase of the virus in advanced liver disease. Hepatology 1993; 18: 16–20.
Dusheiko G, Weiss HS, Brown D, et al. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 1994; 19: 13–18.
Ichimura H, Tamura I, Kurimura O, et al. Hepatitis C virus genotypes, reactivity to recombinant immunoblot assay 2 antigens and liver disease. J Med Virol 1994; 43: 212–215.
Farci P, Melpolder JC, Shimoda A, et al. Studies of HCV quasispecies in patients with acute resolving hepatitis compared to those who progress to chronic hepatitis. Hepatology 1996; 24: 350A.
Coelho-Little ME, Jeffers LJ, Bernstein DE, et al. Hepatitis C virus in alcoholic patients with and without clinically apparent liver disease. Alcohol Clin Exp Res 1995; 19: 1173–1176.
Mendenhall CL, Seeff LB, Diehl AM, et al. Antibodies to hepatitis B virus and hepatitis C virus in alcoholic hepatitis and cirrhosis: their prevalence and clinical relevance. Hepatology 1991; 14: 581–589.
Oshita M, Hayashi N, Kasahara A, et al. Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C. Hepatology 1994; 20: 1115–1120.
Sawada M, Takada A, Takase S, et al. Effects of alcohol on the replication of hepatitis C virus. Alcohol Alcohol 1993; 1B: 85S–90S.
Befrits R, Hedman M, Blomquist L, et al. Chronic hepatitis C in alcoholic patients: prevalence, genotypes, and correlation to liver disease. Scand J Gastroenterol 1995; 30: 1113–1118.
Jenkins PJ, Cromie SL, Roberts SK, et al. Chronic hepatitis C, alcohol and hepatic fibrosis. Hepatology 1996; 24: 153A.
Matsuda Y, Amuro Y, Higashino K, et al. Relation between markers for viral hepatitis and clinical features of Japanese patients with hepatocellular carcinoma: possible role of alcohol in promoting carcinogenesis. Hepatogastroenterology 1995; 42: 151–154.
Noda K, Yoshihara H, Suzuki K, et al. Progression of type C chronic hepatitis to liver cirrhosis and hepatocellular carcinoma: its relationship to alcohol, drinking, and the age of transfusion. Alcohol Clin Exp Res 1996; 20: 95A–100A.
Rosman AS, Paronetto F, Galvin K, et al. Hepatitis C virus antibody in alcoholic patients: association with the presence of portal and/or lobular hepatitis. Arch Intern Med 1993; 153: 965–969.
Ostapowicz G, Watson KJR, Locarnini SA, Desmond PV. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology 1998; 27: 1730–1735.
Schiff ER. Alcoholic patient with hepatitis C virus infection. Am J Med 1999; 107: 95S–99S.
Corrao G, Arico S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology 1998; 27: 914–919.
Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology 1997; 25: 759–768.
Piperno A, Vergani A, Malosio I, et al. Hepatic iron overload in patients with chronic viral hepatitis: role of HFE gene mutations. Hepatology 1998; 28: I 105–1109.
Kazemi-Shiraz L, Datz C, Maier-Dobersberger T, et al. Relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C. Gastroenterology 1999; 116: 127–134.
Smith BC, Grove J, Guzail MA, et al. Heterozygosity for hereditary hemochromatosis is associated with more fiibrosis in chronic hepatitis C. Hepatology 1998; 27: 1695–1699.
Hourigan LF, MacDonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29: 1215–1219.
Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol 1998; 29: 198–206.
Moriya K, Fujie H, Shintani Y, et al. Core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998; 4: 1065–1067.
Schwartz KB, Larroya S, Vogler C, et al. Role of influenza B virus in hepatic steatosis and mitochondrial abnormalities in a mouse model of Reye’s syndrome. Hepatology 1991; 13: 96–103.
Houglum K, Ramm GA, Crawford DH, et al. Excess iron induces hepatic oxidative stress and transforming growth factor betal in genetic hemochromatosis. Hepatology 1997; 26: 605–610.
Niemela O, Parkkila S, Yla-Herttuala S, et al. Sequential acetaldehyde production, lipid peroxidation, and fibrogenesis in micropig model of alcohol-induced liver disease. Hepatology 1995; 22: 1208–1214.
Fong TL, Di Bisceglie AM, Waggoner JG, et al. Significance of antibody to hepatitis C virus in patients with chronic hepatitis B. Hepatology 1991; 14: 64–67.
Chiba T, Matsuzaki Y, Abei M, et al. Role of previous hepatitis B virus infection and heavy smoking in hepatitis C virus-related hepatocellular carcinoma. Am J Gastroenterol 1996; 91: 119–203.
Benvegnu L, Fattovich G, Noventa F, et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Cancer 1994; 27: 2442–2448.
Cacciola I, Pollicino T, Squadrito G, et al. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341: 22–26.
Dieterich DT. Hepatitis C virus and human immunodeficiency virus: clinical issues in coinfection. Am J Med 1999; 107: 79S–84S.
Monga HK, Breauz K, Rodrigues-Barradas MC, Yoffe B. Increased HCV-related morbidity and mortality in HIV patients. Hepatology 1998; 28: 565A.
Serfaty L, Costagliola D, Wendum D, et al. Does HIV infection aggravate chronic hepatitis C in IV drug users? A case-control study. Hepatology 1998; 28: 462A.
Garcia-Samaniego J, Soriano V, Castilla J, et al. Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. The hepatitis /HIV Spanish Study Group. Am J Gastroenterol 1997; 92: 1130–1134.
Hanley JP, Jarvis LM, Andrews J, et al. Investigation of chronic hepatitis C infection in individuals with haemophilia: assessment of invasive and non-invasive methods. Br J Haematol 1996; 94: 159–165.
Benhamou Y, Bochet M, DiMartino V, et al., for the MULTIVIRC Group. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 1999; 30: 1054–1058.
Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463–472.
Serfaty L, Hugues A, Chazouilleres O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998; 27: 1435–1440.
Hu KQ, Tong MJ. Long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999; 29: 1311–1316.
Khan MH, Farrell GC, Byth K, et al. Which patients with hepatitis C develop liver complications? Hepatology 2000; 31: 513–520.
Gines P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7: 122–128.
D’Amico G, Morabito A, Pagliaro L, et al. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986; 31: 468–475.
Magliocchetti N, Torchio P, Corrao G, et al. Prognostic factors for long-term survival in cirrhotic patients after the first episode of liver decompensation. Ital J Gastroenterol Hepatol 1997; 29: 38–46.
Christensen E, Schlichting P, Fauerholdt L, et al. Changes of laboratory variables with time in cirrhosis: prognostic and therapeutic significance. Hepatology 1985; 5: 843–853.
Christensen E, Schlichting P, Fauerholdt L, et al. Prognostic value of ChildTurcotte criteria in medically treated cirrhosis. Hepatology 1984; 4: 430–435.
Cox DR. Regression models and life tables. J R Stat Soc 1972; 34: 187–220.
Christensen E. Multivariate survival analysis using Cox’ s regression model. Hepatology 1987; 7: 1346–1358.
Pugh RNH, Murray-Lyon IM, Dawson JL, et al. Transection of the esophagus for bleeding esophageal varices. Br J Surg 1973; 60: 646–664.
Pasualetti P, Di Lauro G, Festuccia V, et al. Prognostic value of Pugh’s modification of Child-Turcotte classification in patients with cirrhosis of the liver. Panminerva Med 1992; 34: 65–68.
Reisman Y, Gips CH, Lavelle SM. Assessment of liver cirrhosis severity in 1015 patients of the Euricterus database with Campbell-Child, Pugh-Child and with ascites and ascites-nutritional state (ANS) related classifications. Euricterus Project Management Group. Hepatogastroenterology 1997; 44: 1376–1384.
Merkel C, Bolognesi M, Finucci GF, et al. Indocyanine green intrinsic hepatic clearance as a prognostic index of survival in patients with cirrhosis. J Hepatol 1989; 9: 16–22.
Oellerich M, Burdelski M, Lautz HU, et al. Lidocaine metabolite as a measure of liver function in patients with cirrhosis. Ther Drug Monit 1990; 12: 219–226.
Moreli A, Narducci F, Pelli MA, et al. Relationship between aminopyrine breath test and severity of liver disease in cirrhosis. Am J Gastroenterol 1981; 76: 110–113.
Finucci G, Bellon S, Merkel C, et al. Evaluation of splanchnic angiography as a prognostic index of survival in patients with cirrhosis. Scand J Gastroenterol 1991; 91: 951–960.
Vorobioff J, Groszmann RJ, Picabea E, et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology 1996; 11: 701–709.
Merkel C, Gatta A, Zoli M, et al. Prognostic value of galactose elimination capacity, aminopyrine breath test, and ICG clearance in patients with cirrhosis. Comparision with the Pugh score. Dig Dis Sci 1991; 31: 1197–1203.
Katsuyoshi I, Mitchell D, Hann HL, et al. Progressive viral-induced cirrhosis: serial MR imaging findings and clinical correlation. Radiology 1998; 207: 729–735.
Taylor KJW, Gorelick FS, Rosenfield AT, Riely CA. Ultrasonography of chronic liver disease with histological correlation. Radiology 1981; 141: 51–161.
Chan CC, Hwang SJ, Lee FY, et al. Prognostic value of plasma endotoxin levels in patients with cirrhosis. Scand J Gastroenterol 1997; 32: 942–946.
Hoefs JC, Wang F, Kanel G. Functional measurement of nonfibrotic hepatic mass in cirrhotic patients. Am J Gastroenterol 1997; 92: 2054–2058.
Hoefs JC, Green G, Reynolds TB, et al. Mechanism for the abnormal liver scan in acute alcoholic liver injury. Am J Gastroenterol 1984; 79: 950–958.
Hoefs JC, Wang FW, Walker B, Kanel G. Novel, simple method of functional spleen volume calculation by liver-spleen scan. J Nuc Med 1999; 40: 1745–1755.
Bosch J. Medical treatment of portal hypertension. Digestion 1998; 59: 547–555.
Roberts LR, Kamath PS. Pathophysiology of variceal bleeding. Gasteointest Endosc N Am 1999; 9: 167–174.
Hoefs JC, Jonas FM, Sarfeh IJ. Diagnosis and hemodynamic assessment of portal hypertension. Surg Clin North Am 1990; 70: 267–289.
North Italian endoscopic club for the study and treatment of esophageal varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of liver and esophageal varices: a perspective multicenter study. N Engl J Med 1988; 319: 983.
Horisawa M, Goldstein G, Waxman A, Reynolds T. The abnormal hepatic scan of chronic liver disease: its relationship to hepatic hemodynamics and colloid extraction. Gastroenterology 1976; 71: 210–213.
Hoefs JC, Wang F, Kanel G, et al. Perfused Kupffer cell mass: correlation with histology and severity of CLD. Dig Dis Sci 1995; 20: 552–560.
Kodama T, Watanabe K, Hoshi H, et al. Diagnosis of diffuse hepatocellular diseases during SPECT. J Nucl Med 1986; 27: 616–619.
Navasa M, Rimola A, Rodes J. Bacterial infections in liver disease. Semin Liver Dis 1997; 17: 323–333.
Runyon BA. Care of patients with ascites. N Engl J Med 1994; Fed 3: 330: 337–342.
Gines P, Sort P. Patholophysiology of renal dysfunction in cirrhosis. Digestion 1998; 59: 11–15.
Herrera JL. Management of acute liver failure. Dig Dis 1998; 16: 274–283.
Butterworth RF. Pathogenesis of acute hepatic encephalopathy. Digestion 1998; 59: 16–21.
Hoefs JC, Runyon BA. Spontaneous bacterial peritonitis. Dis Mon 1985; 31: 1–48.
Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998; 28: 751–755.
Llovet JM, Bustamente J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29: 62–67.
Ohnishi K, Tanabe Y, Ryu M, et al. Prognosis of hepatocellular carcinoma smaller than 5 cm in relation to treatment: study of 100 patients. Hepatology 1987; 7: 1285–1290.
Akashi Y, Koreeda, Enemoto S, et al. Prognosis of unresectable hepatocellular carcinoma: an evaluation based on multivariate analysis of 90 cases. Hepatology 1991; 14: 262–268.
Gridelli B, Remuzzi G. Strategies for making more organs available for transplantation. N Engl J Med 2000; 343: 404–410.
El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745–750.
Okuda K, Fujimoto I, Hanai A, Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 1987; 47: 4967–4972.
Taylor-Robinson SD, Foster GR, Arora S, et al. Increase in primary liver cancer in the UK, 1979–1994. Lancet 1997; 350: 1142–1143.
Deuffiic S, Poynard T, Buffat L, Valleron AJ. Trends in primary liver cancer. Lancet 1998; 351: 214–215.
Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. Past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31: 777–782.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media New York
About this chapter
Cite this chapter
Everson, G.T. (2002). Natural History of Hepatitis C. In: Koff, R.S., Wu, G.Y. (eds) Chronic Viral Hepatitis. Clinical Gastroenterology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-104-6_4
Download citation
DOI: https://doi.org/10.1007/978-1-59259-104-6_4
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4757-4772-0
Online ISBN: 978-1-59259-104-6
eBook Packages: Springer Book Archive